During an earnings call Tuesday morning, executives at Biogen Inc. brushed off investor concerns about competitors closing in on its key drugs, particularly its treatment approved less than three years ago for spinal muscular atrophy.

Much of the focus of the quarterly earnings report for the three-month period that ended in June was on Spinraza, Biogen’s (Nasdaq: BIIB) SMA drug. The company’s $3.6 billion in second quarter revenue (an 8 percent increase from the same quarter last year) was…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/07/23/biogen-downplays-premature-talk-of-competition-for.html?ana=RSS&s=article_search